Cisplatin, a widely used chemotherapy drug, induces acute kidney injury, which limits its use and efficacy in cancer treatment. However, the molecular mechanism of cisplatin-induced nephrotoxicity is currently unclear. Using pharmacological and gene knockout models, we now demonstrate a pathological role for p53 in cisplatin nephrotoxicity. In C57BL/6 mice, cisplatin treatment induced p53 phosphorylation and protein accumulation, which was accompanied by the development of acute kidney injury. p53 was induced in both proximal and distal tubular cells and partially co-localized with apoptosis. Pifithrin-, a pharmacological inhibitor of p53, suppressed p53 activation and ameliorated kidney injury during cisplatin treatment. Moreover, cisplatin-induced nephrotoxicity was abrogated in p53-deficient mice. Compared with wild-type animals, p53-deficient mice showed a better renal function, less tissue damage, and fewer apoptotic cells. In addition, cisplatin induced less apoptosis in proximal tubular cells isolated from p53-deficient mice than the cells from wild-type animals. Together these results suggest the involvement of p53 in cisplatin-induced renal cell apoptosis and nephrotoxicity.
Introduction
Cisplatin is one of the most widely used and most potent chemotherapeutic agents (5, 33, 39) . It is being used for the treatment of cancers of the testis, ovary, head, neck, lung and many other origins. It is particularly effective in treating testicular and ovarian cancer, with an impressive cure rate (5, 33, 39) . However the use of cisplatin is limited by its side effects in normal tissues, particularly injury to the kidneys (2, 7, 35) . Following cisplatin treatment, over 30% of patients develop renal problems. The nephrotoxicity of cisplatin is indicated by tubular cell death, tissue damage, and the loss of renal function or acute renal failure (1, 3, 9, 16, 19-21, 23, 24, 26, 28, 31, 32, 37, 41, 44, 45) .
While tubular cell death is recognized as a major determinant of cisplatin nephrotoxicity, how these cells are terminally injured under the pathological condition is unclear. In vivo in animals, cisplatin induces both necrosis and apoptosis in renal tubular cells (9, 19, 21, 23, 27, 37, 41) . In vitro in cultured tubular cells, whether apoptosis or/and necrosis is induced depends on the concentrations of cisplatin (20) . Using these experimental models, recent studies have demonstrated the activation of multiple signaling pathways during cisplatin-induced tubular cell injury and nephrotoxicity (1, 3, 16, 19-21, 23, 24, 26, 28, 31, 32, 37, 41, 44, 45) .
One of the cell killing pathways that are activated by cisplatin may involve p53 (5, 33, 39) . p53, as a tumor suppressor protein, can induce apoptosis by transcription of pro-apoptotic genes or by direct interaction and activation of existing pro-apoptotic molecules (22, 25, 38) . In cultured renal tubular cells, p53 is activated by cisplatin (6, (11) (12) (13) (14) 30) . Importantly, cisplatin-induced apoptosis is inhibited by pifithrin-(a pharmacological inhibitor of p53) and also by a dominant negative mutant of p53 (6,
Materials and Methods

Animals. p53-deficient (C57BL/6J-Trp53 tm1Tyj
) and wild-type C57BL/6 mice were originally from the Jackson Laboratory (Bar Harbor, ME). The animals were maintained under conditions of 12/12 hour light/dark cycle with free access to food and water in the animal facility of Veterans Affairs Medical Center at Augusta, GA. For the p53-deficient mouse colonies, genomic DNA samples were extracted from the tail for PCR-based genotyping. Male mice of 8-10 weeks were used in this study. To compare p53-deficient and p53-proficient mice, both littermates and animals from separate colonies were used and the results were similar and thus calculated together.
Cisplatin treatment of animals. In the majority of experiments, cisplatin was freshly prepared in saline at 1 mg/ml and injected intraperitoneally into mice at a dose of 30 mg/kg as previously (8, 41, 42) ; control animals were injected with a comparable volume of saline. In the experiment to test the effects of pifithrin-, pifithrin-was dissolved in DMSO and then mixed with cisplatin solution for intraperitoneal injection; control animals were injected with saline containing DMSO and the cisplatin-only group were injected saline containing DMSO and cisplatin. The dose of pifithrin-(2.2 mg/kg) was chosen accordingly to a previous study (18) .
Renal function and histology. Serum creatinine and blood urine nitrogen (BUN) were determined to monitor renal function as previously (41-43). For histology, kidneys were fixed with 4% paraformaldehyde and stained with hematoxylin-eosin (H & E). Tissues damage was indicated by tubular lysis, dilation, disruption, and cast formation. The TUNEL Assay. Apoptosis in renal tissues was determined by TUNEL assay using the in situ Cell Death Detection kit (Roche Applied Science, Indianapolis, IN) as previously (41-43). Briefly, renal tissues were fixed with 4% paraformaldehyde and paraffinembedded. Tissue sections of 4-µm were exposed to a TUNEL reaction mixture containing terminal deoxynucleotidyl transferase and nucleotides including FITC-labeled dUTP. The slides were examined by fluorescence microscopy.
Immunofluorescence staining. The immunofluorescence staining of kidney tissue was conducted as described in our recent work (41). Briefly, freshly frozen renal tissues were fixed with 4% paraformaldehyde , permeabilized in 1% Triton X-100 and then incubated with a blocking buffer. Subsequently, the samples were incubated with the primary antibodies (anti-p53 or anti-phospho-p53, Cell Signaling, Danvers, MA; anti-active caspase-3, Idun Pharmaceuticals, La Jolla, CA). Finally, the slides were exposed to Cy3 or FITC-labeled secondary antibody (Chemicon, Temecula, CA). For double staining, the tissue sections were first stained for p53 immunofluorescence and then incubated with the TUNEL reaction mixture or FITC-labeled Phaseolus Vulgaris Agglutinin (PHA) or Peanut Agglutinin (PNA) (Vector Laboratories, Burlingame, CA) as described recently (41). The staining was examined by fluorescence and confocal microscopy. Immunoblot analysis showed an increase of total p53 protein in kidney tissue lysates after cisplatin treatment (Fig. 1B) . The increase started from day 2 and intensified at day 3. In parallel to p53 accumulation, there was p53 phosphorylation (Fig. 1C) .
In immunofluorescence analysis, p53 accumulation and phosphorylation were shown mainly in renal cortical cell nucleus (Fig. 1C) . The results suggest that p53 is phosphorylated, stabilized, and accumulated to nucleus during cisplatin nephrotoxicity.
Localization of p53 activation in renal tubular cells during cisplatin nephrotoxicity.
Immunofluorescence staining showed p53 induction in the cells of renal cortex and outer medulla, but not in the inner medulla (not shown). In addition, p53 was not induced in glomeruli (not shown). To further identify the cell types that induced p53, we determined whether p53 was induced in proximal tubules or distal tubules in renal cortex. To this end, we co-stained p53 with either FITC-labeled PHA or PNA, lectins that specifically bind proximal and distal tubular cells respectively (4, 34, 41). As shown in Fig Co-localization of p53 induction with tubular cell apoptosis.
Using in vitro models of cultured cells, previous studies have suggested the involvement of p53 in tubular cell apoptosis during cisplatin treatment (6, (11) (12) (13) (14) 30) . To determine the relationship between p53 induction and tubular cell apoptosis in vivo, we examined p53 and apoptosis in the same tissues by immunofluorescence and TUNEL assay ( 
Suppression of cisplatin nephrotoxicity by pifithrin-.
Pifithrin-is a pharmacological inhibitor of p53 (18) . To determine the role of p53 in cisplatin nephrotoxicity in vivo, we initially examined the effects of pifithrin-N in C57BL/6 mice. As shown in Fig. 4A , cisplatin-induced p53 accumulation and phosphorylation in kidney tissues were suppressed by co-administration of pifithrinImportantly, the development of acute renal failure during cisplatin treatment was ameliorated by pifithrin-. BUN was decreased from 135 mg/dL in cisplatin-treated animals to 70 mg/dL in cisplatin+pifithrin-P treated group Q Fig. 5A ). Consistently, serum 
Amelioration of cisplatin nephrotoxicity in p53-deficient mice.
To further examine the role played by p53 in cisplatin nephrotoxicity, we tested a p53 knockout mouse model. p53 deficiency in these animals was confirmed by PCR-based genotyping (not shown). In addition, cisplatin induced p53 in kidney tissues of wild-type (WT) but not the gene knockout (KO) animals ( In this study, p53 activation started at day 2 of cisplatin treatment and was intensified at day 3, showing a temporal correlation with the development of renal injury and renal failure. In addition, p53 was shown to be activated in renal tubular cells, the main cell types that were injured by cisplatin. Co-staining with FITC-labeled lectins specific for proximal and distal tubules indicated that p53 was induced in both proximal and distal tubular cells under the pathological condition (Fig. 2) . Although earlier work suggested that distal tubules were the primary site of apoptosis during cisplatin nephrotoxicity (23) , more recent studies also showed apoptosis in proximal tubules (19, 37) . Cisplatin-induced apoptosis in proximal tubules was further detected in our latest work by co-localizing apoptotic cells with PHA lectin staining. Thus the spatial analysis of p53 activation is consistent with the involvement of p53 in cisplatin-induced renal tubular cell injury. This inference is further supported by our results showing that the cells that had p53 activation underwent apoptosis as indicated by positive TUNEL staining (Fig. 3) . Of note, while TUNEL staining may not be very specific for apoptosis,
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it has been demonstrated to be relatively specific for apoptosis analysis in acute kidney injury induced by renal ischemia and cisplatin (17) .
With clear evidence for p53 activation as indicated by its phosphorylation and protein accumulation, this study has not investigated the mechanism of p53 activation during cisplatin nephrotoxicity. For a mechanistic study, it would be preferable to be initially conducted in in vitro models. Nevertheless, it can be speculated that cisplatin may induce DNA damage by its intra-and inter-strand cross-linking property (5, 33, 39) .
This may then activate the signaling pathways of DNA damage response including ATM and ATR, leading to p53 phosphorylation and activation. Our recent work has shown the cleavage and inactivation of ATM, but not ATR, during cisplatin treatment of renal tubular cells (40) . However, the role of ATM and ATR in p53 activation under these experimental conditions remains to be clarified. It is also noteworthy that, in addition of DNA damage, cisplatin may activate p53 via other injury or stress related signaling pathways (38) . In this regard, our recent work demonstrated the inhibitory effects of free radical scavenging chemicals on p53 activation and cisplatin-induced nephrotoxicity, suggesting that oxidative stress may contributes to p53 activation (12).
Our results showed significant protective effects of pifithrin-on cisplatin nephrotoxicity (Figs. 4-6 ). Moreover, p53-deficeint mice were shown to be resistant to cisplatin injury (Figs. 7-8 ). The effects of pifithrin-and p53 deficiency were shown at the levels of renal function, histology, and tubular cell apoptosis. Nevertheless, it is important to recognize that the protective effects were only partial. This is not surprising as the pathogenesis of cisplatin nephrotoxicity is generally considered to be multifactorial. Indeed, our results showed that, while many apoptotic cells in cisplatin-treated tissues had p53 induction, others did not induce p53 (Fig. 3) , suggesting that apoptosis of the latter cell population is independent of p53. Consistently, in primary cultures of proximal tubular cells, p53-deficiency did not completely block cisplatininduced apoptosis (Fig. 9) . It is important to recognize that Tubular cell apoptosis during acute kidney injury is dynamic and progressive. Thus analysis of apoptosis at a fixed time-point (as in our study) only shows a snapshot image (17), which likely underestimates the amount of apoptotic cells developing during the whole study period of 3 days. As a result, partial protection of apoptosis may have significant effects on renal histology and function.
In addition, we noticed that the p53-deficient mice used in our experiments can be roughly divided into two groups, depending on their sensitivity to cisplatin injury. One group (about two-third of the tested animals) was clearly resistant to cisplatin injury and only showed small to moderate increases of BUN and serum creatinine at day 3 of cisplatin treatment. In contrast, the other group (about one-third of the tested animals)
showed medium to severe renal injury and renal failure during cisplatin treatment, which was comparable to wild-type animals. Frequently both resistant and sensitive animals were found in the same litter, suggesting that the variation was not due to the abnormality of specific litters. It was reported that the developing kidneys of p53-deficient mice had structural abnormalities including hyperplastic cyst formation in the differentiated zone (29). Our study used young adult mice, which did not show obvious structural or functional abnormalities in the kidneys. Occasionally there were renal cysts, but the majority of the animals were normal. While the exact cause of the varied cisplatin sensitivity in p53-deficient mice is unclear, knockout of p53 is expected to promote cancer development. According to the information from Jackson Laboratory, the p53-deficient mice develop tumors (principally lymphomas and osteosarcoma) at around 3-6 months of age. In our study, the animals were used at 8-10 weeks (2-2.5 months). Thus it is possible that some of the animals had already undergone homeostatic changes of early tumor development by the time of experiment, which may affect their sensitivity to cisplatin. It would be advantageous to use conditional p53 knockout models that specifically down-regulate p53 in renal tubular cells to further investigate this possibility and determine the role of p53 in cisplatin nephrotoxicity.
The involvement of p53 in cisplatin nephrotoxicity suggests that it is possible to protect kidneys during cisplatin chemotherapy by blocking p53. However, we have to recognize that inhibition of p53 may also limit apoptosis of cancer cells and thus reduce the therapeutic effects in tumors. In this regard, over 50% of cancers have p53 mutations, yet cisplatin is frequently effective in treating them, indicating that cisplatin therapy in these cancer types may not be stringently p53-dependent (10, 33). During cisplatin therapy of these cancers, targeting p53 should be a useful strategy for renoprotection. On the other hand, in cancers where the therapeutic effects of cisplatin depend on p53, restrictive renal delivery of p53 inhibitory chemicals, antisense oligonucleotides and siRNAs may be considered. Renal tissues have an enormous capacity of reabsorption and are thus particularly accessible to drugs including antisense oligonucleotides and siRNA (36). Whether these p53-targeting approaches can protect kidneys against cisplatin nephrotoxicity without limiting the therapeutic effects in cancers warrants further investigation. 
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